Abstract: The specification discloses modified Clostridial toxins comprising a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and an enhanced Clostridial toxin binding domain; polynucleotide molecules encoding such modified Clostridial toxins; and method of producing such modified Clostridial toxins.
Type:
Grant
Filed:
August 15, 2008
Date of Patent:
September 20, 2011
Assignee:
Allergan, Inc.
Inventors:
Lance E. Steward, Ester Fernandez-Salas, Joseph Francis, Shengwen Li, Marcella A. Gilmore, Kei Roger Aoki
Abstract: Agents for treating pain, methods for producing the agents and methods for treating pain by administration to a patient of a therapeutically effective amount of the agent. The agent can include a clostridial neurotoxin, or a component or fragment or derivative thereof, attached to a targeting moiety, wherein the targeting moiety is selected from a group consisting of transmission compounds which can be released from neurons upon the transmission of pain signals by the neurons, and compounds substantially similar to the transmission compounds.
Abstract: The present invention relates to a toxin comprising a modified light chain of a botulinum toxin type E, wherein the modified light chain comprises amino acid sequence PFVNKQFN (SEQ ID NO: 120) at the N-terminus, and amino acid sequence xDxxxLL (SEQ ID NO: 111) at the C-terminus, wherein x is any amino acid.
Type:
Grant
Filed:
January 8, 2010
Date of Patent:
September 13, 2011
Inventors:
Ester Fernandez-Salas, Lance E. Steward, Todd Herrington, K. Roger Aoki
Abstract: The present invention provides clostridial toxin substrates useful in assaying for the protease activity of any clostridial toxin, including botulinum toxins of all serotypes as well as tetanus toxins. A clostridial toxin substrate of the invention contains a donor fluorophore; an acceptor having an absorbance spectrum overlapping the emission spectrum of the donor fluorophore; and a clostridial toxin recognition sequence that includes a cleavage site, where the cleavage site intervenes between the donor fluorophore and the acceptor and where, under the appropriate conditions, resonance energy transfer is exhibited between the donor fluorophore and the acceptor.
Type:
Grant
Filed:
November 17, 2009
Date of Patent:
September 6, 2011
Assignee:
Allergan, Inc.
Inventors:
Lance E. Steward, Ester Fernandez-Salas, Kei Roger Aoki
Abstract: The present invention relates to a toxin comprising a modified light chain of a botulinum toxin type E, wherein the modified light chain comprises amino acid sequence PFVNKQFN (SEQ ID NO: 120) at the N-terminus, and amino acid sequence xExxxLL (SEQ ID NO: 112) at the C-terminus, wherein x is any amino acid.
Type:
Grant
Filed:
January 8, 2010
Date of Patent:
August 30, 2011
Assignee:
Allergan, Inc.
Inventors:
Ester Fernandez-Salas, Lance E. Steward, Todd Herrington, K. Roger Aoki
Abstract: The present invention provides clostridial toxin substrates useful in assaying for the protease activity of any clostridial toxin, including botulinum toxins of all serotypes as well as tetanus toxins. A clostridial toxin substrate of the invention contains a donor fluorophore; an acceptor having an absorbance spectrum overlapping the emission spectrum of the donor fluorophore; and a clostridial toxin recognition sequence that includes a cleavage site, where the cleavage site intervenes between the donor fluorophore and the acceptor and where, under the appropriate conditions, resonance energy transfer is exhibited between the donor fluorophore and the acceptor.
Type:
Grant
Filed:
November 17, 2009
Date of Patent:
August 23, 2011
Assignee:
Allergan, Inc.
Inventors:
Lance E. Steward, Ester Fernandez-Salas, Kei Roger Aoki
Abstract: Compositions comprising activatable recombinant neurotoxins and polypeptides derived therefrom. The invention also comprises nucleic acids encoding such polypeptides, and methods of making such polypeptides and nucleic acids.
Type:
Grant
Filed:
August 22, 2008
Date of Patent:
August 23, 2011
Assignee:
Allergan, Inc.
Inventors:
J. Oliver Dolly, Yan Li, Kuo Chion Chan
Abstract: The present invention provides a method of determining the proximity, or changes in the proximity of two or more molecular features labeled with fluorophores able to undergo DARET. In preferred embodiments the change in proximity of molecular features in a sample is correlated with changes in the fluorescence polarization of the sample, and may be monitored in real time.
Type:
Grant
Filed:
October 11, 2006
Date of Patent:
August 16, 2011
Assignee:
Allergan, Inc.
Inventors:
Marcella A. Gilmore, Dudley J. Williams, Lance E. Steward, Kei Roger Aoki
Abstract: The specification discloses modified Clostridial toxins comprising a PAR ligand domain, a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and a Clostridial toxin binding domain; polynucleotide molecules encoding modified Clostridial toxins comprising a PAR ligand domain, a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and a Clostridial toxin binding domain; and method of producing modified Clostridial toxins comprising a PAR ligand domain, a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and a Clostridial toxin binding domain.
Type:
Grant
Filed:
August 15, 2008
Date of Patent:
August 16, 2011
Assignee:
Allergan, Inc.
Inventors:
Lance E. Steward, Ester G. Fernandez-Salas, Marcella A. Gilmore, Joseph Francis, Shengwen Li, Kei Roger Aoki
Abstract: The invention provides modified Clostridial toxins comprising a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain, a translocation facilitating domain and an altered target domain; polynucleotide molecules encoding such modified Clostridial toxins; and methods of producing such modified Clostridial toxins.
Type:
Grant
Filed:
July 11, 2007
Date of Patent:
August 9, 2011
Assignee:
Allergan, Inc.
Inventors:
Lance E. Steward, Joseph Francis, Ester G. Fernandez-Salas, Marcella A. Gilmore, Shengwen Li, Kei Roger Aoki
Abstract: Compositions comprising activatable recombinant neurotoxins and polypeptides derived therefrom. The invention also comprises nucleic acids encoding such polypeptides, and methods of making such polypeptides and nucleic acids.
Type:
Grant
Filed:
August 18, 2008
Date of Patent:
July 26, 2011
Assignee:
Allergan, Inc.
Inventors:
J. Oliver Dolly, Yan Li, Kuo Chion Chan
Abstract: Botulinum toxin, among other presynaptic neurotoxins is used for the treatment and prevention of migraine and other headaches associated with vascular disorders. Presynaptic neurotoxins are delivered focally, targeting the sphenopalatine ganglion. Exemplary delivery is carried out by way of injection.
Abstract: The present invention provides BoNT/B peptides, BoNT/B peptide compositions, tolerogizing compositions, immune response inducing compositions, as well as methods of determining immunoresistance to botulinum toxin therapy in an individual, methods of treating immunoresistance to botulinum toxin therapy in an individual, methods of reducing anti-botulinum toxin antibodies in an individual and methods of inducing a BoNT/B immune response an individual.
Type:
Grant
Filed:
January 6, 2010
Date of Patent:
July 5, 2011
Assignees:
Allergan, Inc., Baylor College of Medicine
Abstract: The present invention provides BoNT/B peptides, BoNT/B peptide compositions, tolerogizing compositions, immune response inducing compositions, as well as methods of determining immunoresistance to botulinum toxin therapy in an individual, methods of treating immunoresistance to botulinum toxin therapy in an individual, methods of reducing anti-botulinum toxin antibodies in an individual and methods of inducing a BoNT/B immune response an individual.
Type:
Grant
Filed:
January 6, 2010
Date of Patent:
June 28, 2011
Assignees:
Allergan, Inc., Baylor College of Medicine
Abstract: Compositions comprising activatable recombinant neurotoxins and polypeptides derived therefrom. The invention also comprises nucleic acids encoding such polypeptides, and methods of making such polypeptides and nucleic acids.
Type:
Grant
Filed:
July 30, 2008
Date of Patent:
June 14, 2011
Assignee:
Allergan, Inc.
Inventors:
J. Oliver Dolly, Yan Li, Kuo Chion Chan
Abstract: Methods for treating gastric disorders, such as GERD and delayed gastric emptying, by intramuscular administration of a botulinum toxin to a head, neck and/or shoulder muscle of a patient with a gastric disorder.
Abstract: Compositions comprising activatable recombinant neurotoxins and polypeptides derived therefrom. The invention also comprises nucleic acids encoding such polypeptides, and methods of making such polypeptides and nucleic acids.
Type:
Grant
Filed:
August 27, 2007
Date of Patent:
March 1, 2011
Assignee:
Allergan, Inc.
Inventors:
Lance E. Steward, Joseph Francis, Ester Fernandez-Salas, Sanjiv Ghanshani, Marcella A. Gilmore, Shengwen Li, J. Oliver Dolly, Kei Roger Aoki
Abstract: The present invention discloses modified neurotoxins with altered biological persistence. In one embodiment, the modified neurotoxins are derived from Clostridial botulinum toxins. Such modified neurotoxins may be employed in treating various conditions, including but not limited to muscular disorders, hyperhidrosis, and pain.
Type:
Grant
Filed:
January 17, 2007
Date of Patent:
February 22, 2011
Assignee:
Allergan, Inc.
Inventors:
Lance E. Steward, Ester Fernandez-Salas, Athena Spanoyannis, K. Roger Aoki, Wei-Jen Lin
Abstract: The specification discloses modified Clostridial toxins comprising a PAR ligand domain, a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and a Clostridial toxin binding domain; polynucleotide molecules encoding modified Clostridial toxins comprising a PAR ligand domain, a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and a Clostridial toxin binding domain; and method of producing modified Clostridial toxins comprising a PAR ligand domain, a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and a Clostridial toxin binding domain.
Type:
Grant
Filed:
September 1, 2005
Date of Patent:
February 22, 2011
Assignee:
Allergan, Inc.
Inventors:
Lance E. Steward, Ester G. Fernandez-Salas, Marcella A. Gilmore, Joseph Francis, Shengwen Li, Kei Roger Aoki
Abstract: The present invention discloses modified neurotoxins with altered biological persistence. In one embodiment, the modified neurotoxins are derived from Clostridial botulinum toxins. Such modified neurotoxins may be employed in treating various conditions, including but not limited to muscular disorders, hyperhidrosis, and pain.
Type:
Grant
Filed:
January 17, 2007
Date of Patent:
February 15, 2011
Assignee:
Allergan, Inc.
Inventors:
Lance E. Steward, Ester Fernandez-Salas, Athena Spanoyannis, K. Roger Aoki, Wei-Jen Lin